75,000 yearly average for new patients, representing all tumor types
3,000+ patients on average enrolled on clinical trials per year
Sarah Cannon provides the following centralized services to these sites:
Study Activation - Sarah Cannon Study Activation department communicates with industry sponsors and CRO’s on behalf of strategic sites. This department centrally coordinates and project manages all study start-up activities from the initial Confidential Disclosure Agreement (CDA) and feasibility completion all the way to SIV and site activation.
Contract and Financial – Negotiation and execution of protocol-specific budgets and contracts; invoice sponsor organizations; payment distribution to sites
Clinical Operations Support– Provide planning, implementation and support to site through Sarah Cannon leadership team
Regulatory Affairs & Safety – Sarah Cannon centrally processes all initial regulatory documents for all Start-Up activities and many of the Maintenance documents for Strategic Sites. In addition to Regulatory services, Sarah Cannon also provides a central Safety processing group that works directly with Sponsors for timely processing of all IND Safety Reports as well as uploading these reports into a central database for PI review and acknowledgement.
Quality Assurance – Sarah Cannon offers a comprehensive quality plan for each investigative site. The quality plan encompasses routine periodic auditing, as well as trending and ensuring resolution of audit observations. In addition to auditing services, quality team members partner with the sites to support SOP creation, revision and review cycles. The quality team members provide assistance to the sites with preparation and hosting of external audits / inspections, and consult on issues that arise during the course of a study.
Education – Sarah Cannon provides the investigative sites with access to TransCelerate approved GCP training as well as comprehensive curriculum for educational opportunities in both general research and therapeutic areas.
Located in middle Tennessee with 25 practice locations
Clinical research is conducted at 14 locations which are staffed with oncology research nurses.
50 community-based Medical Oncologists
13,000 new patients each year, representing all tumor types
This practice has capabilities and experience in conducting clinical trials in phases I-IV.
On average, 1,250 patients are enrolled annually.
Sponsor monitoring is conducted out of one central office (250 25th Avenue North, Suite 310, Nashville, TN). Original charts and CRF’s are couriered to the central location for the monitoring.
Site has centralized pharmacy for drug shipment, staffed by a dedicated research pharmacist. Drug is then transported to the other clinic locations once a patient has been identified, screened, and is ready to enroll.
FCS serves patients on the Gulf Coast from Naples to Tallahassee, Central Florida and on the East Coast from Palm Beach County to Jacksonville. There are nearly 100 locations within the FCS network.
Clinical research is conducted at 36 locations with a highly-skilled research staff of oncology research nurses and staff.
150 community-based Medical Oncologists and 120+ APRNs and PA-Cs.
35,000 new patients each year, representing all tumor types
This practice has capabilities and experience in conducting clinical trials in phases I-IV.
On average, 500 patients are enrolled annually.
Sponsor monitoring is conducted at centralized monitoring locations per region. EMR is used for protocol orders and source documentation. Electronic medical records are accessed at the central location for monitoring.
Site has centralized pharmacy at each region for drug shipment. Drug is then transported to the other clinic locations once a patient has been identified, screened, and is ready to enroll.
Located in Chattanooga, TN with 3 practice locations
Clinical research is conducted in 2 locations, all of which are staffed with oncology research nurses.
11 community-based Medical Oncologists
4,000 new patients each year, representing all tumor types
This practice has capabilities and experience in conducting phase II, III, and IV clinical trials.
On average, 80 patients are enrolled annually.
Sponsor monitoring is conducted out of one central office (605 Glenwood Drive, Suite 200 Chattanooga, TN 37404). Original charts and CRF’s are couriered to the central office for review.
Site has centralized pharmacy for drug shipment. Drug is then transported to the other clinic locations once a patient has been identified, screened, and is ready to enroll.
Clinical research initiated at Menorah Medical Center, Research Medical Center and Centerpoint Medical Center at HCA Midwest Health, a partner in the Sarah Cannon Cancer Network.
The research program is supported and complemented by the health system’s seven hospitals and cancer care outreach sites located in communities throughout metropolitan Kansas City and the surrounding area.
The research program has capabilities and experience in conducting clinical trials for both hematology and solid tumor.
Site investigators include 13 community-based medical oncologists, 1 hematologist, 2 GYN oncologists and 1 neuro oncologist.
Sponsor monitoring is conducted out of one central administrative office. Original charts and regulatory documents are provided at the central location for monitoring.
Site has centralized pharmacy for investigational drug shipment. Investigational drug is then transported to the other clinic locations once a patient has been identified, screened and ready to enroll.
Clinical trials will be offered as a part of HOC’s oncology services at its newly constructed 17,000 square-foot oncology facility in Baton Rouge, La., which includes 20 exam rooms and 37 chemotherapy chairs.
HOC offers in-house laboratory, pathology and oral pharmacy services all under one roof so that patients can receive the care they need in one location.
The practice also offers 24/7 care management to patients through their affiliation with AON.
The practice’s highly trained and experienced clinical staff consists of Nurse Practitioners, Oncology Certified Registered Nurses and Licensed Practical Nurses.
HOC medical oncologists serving patients in Baton Rouge are Dr. Gerald Miletello, Dr. Christopher McCanless, Dr. Michael Castine, III, Dr. Pavani Ellipeddi, Dr. Lauren Juneja and Dr. Sanjay Juneja.
The physicians at Messino Cancer Centers (MCC) have a 30-year history of providing high-quality care to patients in the community setting.
MCC serves patients at state-of-the-art locations throughout Western North Carolina with six cancer centers in Asheville, Brevard, Franklin, Marion, Spruce Pine and Sylva.
The MCC staff is comprised of 16 experienced physicians, advanced practice providers, nurses and a clinical support staff dedicated to providing innovative treatments.
Its physicians provide cutting-edge, evidence-based treatment that incorporates personalized medicine, palliative care, standard and nationally accepted guidelines, and clinical trials.
The palliative care team works closely with the team of oncologists, advanced practitioners, nurses, dietitian and behavioral therapist ensuring patients have resources to handle the physical, emotional and psychological aspects of their cancer diagnosis.
Clinical trial services are offered in one central location in Asheville.
Located in Columbus, Ohio, the Zangmeister Cancer Center (ZCC) offers comprehensive cancer and hematology treatment in one location close to home.
It adheres to a holistic approach while providing outpatient treatment for cancer and blood disorders. Its other services include diagnostic imaging, offering most patients access to all of their cancer care under one roof.
The center also offers genetic risk evaluations, chemotherapy treatment and other infusions, targeted therapy and immunotherapy, laboratory services, a specialty pharmacy, care management including social support services and consolidated research care.
ZCC’s 13 highly skilled and compassionate physicians use the latest advancements in the diagnosis, treatment and prevention of cancer and blood disorders.
The clinic’s palliative team often serves as their patients’ advocate, helping them understand and manage the issues and problems that accompany the diagnosis and treatment of cancer.
With ten locations in Arkansas, Genesis Cancer and Blood Institute (GCBI) cares for patients in Hot Springs and the surrounding communities.
For close to 30 years, GCBI has been participating in clinical trials delivering the most advanced cancer treatments customized for each patient. Having in-house laboratory, pathology and oral pharmacy services makes it easier for patients to receive the care they need in one location as well as access to an expanded menu of clinical trials.
GCBI’s six physicians emphasize clinical trials and education, and closely monitor results from trials performed domestically and internationally.
Clinical trials are offered at its Hot Springs locations.